Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07271485 · ClinicalTrials.gov registry record · Early Phase 1

Propranolol for Misophonia

A Early Phase 1 study of Misophonia and Propanolol, sponsored by Bloom Mental Health.

Recruiting
Registry status
Early Phase 1
Development phase
20
Enrollment target
1
Study location

NCT07271485 is a Early Phase 1 study of Misophonia and Propanolol that is actively recruiting participants, run by Bloom Mental Health. The registered enrollment target is 20 participants, below the 55-participant average among 7 other Misophonia trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07271485, a Early Phase 1 study of Misophonia and Propanolol, is actively recruiting participants, sponsored by Bloom Mental Health.

RECRUITING
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia. The secondary goals of this study are: 1. Determine potential predictors of response to propranolol treatment, including demographic factors, baseline symptom severity, psychometric instrument item responses, and physiological characteristics. 2. Evaluate the safety and tolerability of propranolol in individuals with misophonia.

Interventions

  • DRUG Placebo
  • DRUG propranolol

Study Locations (1)

Colorado

  • Bloom Mental Health - Littleton

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2025-12-19
Est. Completion 2026-12-19
Phase Early Phase 1

Sponsor

Bloom Mental Health

1 total trials

What the Registry Record Tells You About NCT07271485

The ClinicalTrials.gov registry entry for NCT07271485 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55-participant average among 7 other Misophonia trials with a reported enrollment target (64% lower). The listed sponsor is Bloom Mental Health, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Misophonia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07271485 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT07271485 about?

NCT07271485 is a clinical study titled "Propranolol for Misophonia". The primary goal of this study is to investigate whether a one-time dose of 20 mg oral propranolol can temporarily reduce the adverse emotional and physical symptoms triggered by misophonia. The secondary goals of this study are: 1. Determine potential predictors of response to propranolol treatme...

What is the current status of trial NCT07271485?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2025-12-19. Estimated completion is 2026-12-19.

What conditions does trial NCT07271485 study?

This clinical trial studies the following conditions: Misophonia, Propanolol, Misophonia Treatment.

What interventions are being tested in trial NCT07271485?

The interventions under investigation include: Placebo (DRUG), propranolol (DRUG).

Who is sponsoring clinical trial NCT07271485?

This trial is sponsored by Bloom Mental Health, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07271485 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Misophonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.